Treatment Paradigms in Neovascular AMD
Age-related macular degeneration (AMD) affects more than 7 million individuals in the USA, making it the most common cause of visual impairment among adults over 60 years of age. Although the precise mechanisms responsible for the development of AMD are not fully understood, it is well established that vascular endothelial growth factor (VEGF) plays a major role in the development and growth of the choroidal neovascular membrane. Anti-VEGF treatment has become the corner stone of management of this condition. In this article we discuss the current evidence for the various treatment paradigms presently in practical use, including the frequency of anti-VEGF injections as well as the use of combination treatments.
Supplementary Material (0)
- Stein JD, VanderBeek BL, Talwar N, et al. Rates of nonexudative and exudative age-related macular degeneration among Asian American ethnic groups. Investig Ophthalmol Vis Sci. 2011;52:6842–8. CrossRef
- Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 2007;114:92–8. CrossRef
- Finger RP, Fimmers R, Holz FG, et al. Incidence of blindness and severe visual impairment in Germany: projections for 2030. Investig Ophthalmol Vis Sci. 2011;52:4381–9. CrossRef
- Minassian DC, Reidy A, Lightstone A, et al. Modelling the prevalence of age-related macular degeneration (2010–2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy. Br J Ophthalmol. 2011;95:1433–6. CrossRef
- Klein R, Knudtson MD, Lee KE, et al. Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology. 2008;115:1460–7. CrossRef
- Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385–9.
- Tuo J, Ning B, Bojanowski CM, et al. Synergic effect of polymorphisms in ERCC6 5′ flanking region and complement factor H on age-related macular degeneration predisposition. Proc Natl Acad Sci USA. 2006;103:9256–61. CrossRef
- Klein R. Overview of progress in the epidemiology of age-related macular degeneration. Ophthalmic Epidemiol. 2007;14:184–7. CrossRef
- Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486–95. CrossRef
- Hollyfield JG, Bonilha VL, Rayborn ME, et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat Med. 2008;14:194–8. CrossRef
- Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004;122(4):598–614.
- Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64(1):162–9.
- Apte RS. Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother. 2008;9(3):499–508.
- Wang Y, Fei D, Vanderlaan M, et al. Biological activity of Bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7:335–45. CrossRef
- Ferrara N, Damico L, Shams N, et al. Development of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Phila, Pa). 2006;26:859–70. CrossRef
- Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of Bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508–12. CrossRef
- Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:1522.e1–14. CrossRef
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31. CrossRef
- Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus Verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR Study. OPHTHA. 2009;116:57.e5–65.e5.
- Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239–48. CrossRef
- Bolz M. Ranibizumab EXCITE Study: exploring the value of optical coherence tomography for the management of Ranibizumab therapy in age-related macular degeneration. In: 8th EURETINA congress, Vienna, 2008.
- Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of Ranibizumab in subjects with neovascular age-related macular degeneration. OPHTHA. 2009;116:1731–9. CrossRef
- Meyer CH, Eter N, Holz FG, et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial. The Invest Ophthalmol Vis Sci 2008;49:E-Abstract 273.
- CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and Bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908. CrossRef
- • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, et al. Ranibizumab and Bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–98. This study showed that ranibizumab and bevacizumab had similar effects on visual acuity over a 2-year period. In addition, this paper showed that only small differences in mean gain in visual acuity emerged between dosing regimens.
- Vascular endothelial growth factor (VEGF) trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (AMD)—full text view—ClinicalTrials.gov.clinicaltrialsgov. http://clinicaltrials.gov/ct2/show/NCT00637377. Accessed 27 Sep 2012.
- Vascular endothelial growth factor VEGF trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (AMD)—full text view—ClinicalTrials.gov.clinicaltrialsgov. http://clinicaltrials.gov/ct2/show/NCT00509795. Accessed 27 Sep 2012.
- Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. AJOPHT. 2007;144:850–7.
- Kaiser PK, Blodi BA, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA Study of Ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:1868–75. CrossRef
- Sadda SR, Stoller G, Boyer DS, et al. Anatomical benefit from Ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Retina (Phila, Pa). 2010;30:1390–9. CrossRef
- • Singer MA, Awh CC, Sadda SV, et al. HORIZON: an open-label extension trial of Ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. OPHTHA. 2012;119:1175–83. This study is the extension study evaluating the long-term (>2 years) frequency, safety, tolerability, and efficacy of multiple intravitreal injections of ranibizumab in patients who had completed the controlled, randomized treatment phase of the MARINA, ANCHOR, or FOCUS trial.
- Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus Bevacizumab to treat neovascular age-related macular degeneration. OPHTHA. 2012;119:1399–411. CrossRef
- Abraham P, Yue H. Randomized, double-masked, sham-controlled trial of Ranibizumab for neovascular age-related macular degeneration: PIER Study year 2. Am J Ophthalmol. 2010;150(3):315–24.
- Lalwani GA, Rosenfeld PJ, Fung AE. A variable-dosing regimen with intravitreal Ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43–58.e1.
- • Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of Ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study. Ophthalmology. 2011;118(4):663–71. This study demonstrated that individualized treatment with less than monthly re-treatments shows a similar safety profile as observed in previous randomized clinical trials with monthly ranibizumab treatment.
- Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679–80. CrossRef
- Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using Ranibizumab for neovascular age-related macular degeneration. OPHTHA. 2010;117:2134–40. CrossRef
- • Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus Ranibizumab for choroidal neovascularization in age-related macular degeneration. OPHTHA. 2012;119:1001–10. This study concluded that ranibizumab monotherapy or combined with verteporfin PDT improved BCVA at month 12; however, noninferiority (7-letter margin) of combination regimens to ranibizumab monotherapy was not demonstrated.
- Ávila MP, Farah ME, Santos A, et al. Three-year safety and visual acuity results of epimacular 90strontium/90yttrium brachytherapy with Bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Retina. 2012;32(1):10–8. CrossRef
- • Moshfeghi AA, Morales-Canton V, Quiroz-Mercado H, et al. 16 Gy low-voltage X-ray irradiation followed by as needed Ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a ‘radiation-first’ strategy. Br J Ophthalmol. doi:10.1136/bjophthalmol-2011-301222 This study showed that after 12 months, non-invasive, low- voltage X-ray irradiation with as needed ranibizumab rescue therapy demonstrated good safety with a visual acuity stabilizing effect and reduction in retinal thickness in patients with neovascular AMD.
- Orayainccom. http://www.orayainc.com/wp-content/uploads/2012/05/Oraya-INTREPID-Press-Release.pdf. Accessed 2 Oct 2012.
- INTREPID—IRay Plus Anti-VEGF Treatment For Patients With Wet AMD—Full Text View—ClinicalTrials.gov. clinicaltrialsgov. http://clinicaltrials.gov/ct2/show/NCT01016873?term=oraya&rank=2. Accessed 2 Oct 2012.
- Ophthotech’s Novel Anti-PDGF Combination Agent FovistaTM Demonstrated Superior Efficacy over Lucentis® Monotherapy in Large Controlled Wet AMD Trial | Business Wire. businesswire.com. http://www.businesswire.com/news/home/20120613005333/en/Ophthotech%E2%80%99s-Anti-PDGF-Combination-Agent-FovistaTM-Demonstrated-Superior. Accessed 2 Oct 2012.
- Lassota N. Clinical and histological aspects of CNV formation: studies in an animal model. Acta Ophthalmol. 2008;86 Thesis 2:1–24.
- Colucciello M. Intravitreal Bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: short-term optical coherence tomography results. J Ocul Pharmacol Ther. 2008;24:15–24. CrossRef
- Jonas JB, Libondi T, Golubkina L, et al. Combined intravitreal Bevacizumab and triamcinolone in exudative age-related macular degeneration. Acta Ophthalmol. 2009;88:630–4.
- • Rouvas AA, Papakostas TD, Vavvas D, et al. Intravitreal Ranibizumab, intravitreal Ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. Retina (Phila, Pa) 2009;29:536–44. This paper showed that combination treatment for patients with RAP lesions, resulted in stabilization of the disease. There was a significant trend towards better visual acuity and anatomic restoration of the affected area was observed in the intravitreal triamcinolone and PDT group.
About this Article
- Treatment Paradigms in Neovascular AMD
Current Ophthalmology Reports
Volume 1, Issue 1 , pp 12-19
- Cover Date
- Online ISSN
- Current Science Inc.
- Additional Links
- Neovascular AMD
- Treatment paradigms
- Combination treatment
- Triple therapy
- PEDF inhibitors